| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/09/2011 | US20110135598 Methods to diagnose and immunize against the virus causing human merkel cell carcinoma |
| 06/09/2011 | US20110135597 Uses of Mammalian Cytokine; Related Reagents |
| 06/09/2011 | US20110135596 Fusion protein comprising ubiquitin or ubiquitin-like protein, membrane translocation sequence and biologically active molecule and use thereof |
| 06/09/2011 | US20110135595 Neuregulin based methods and compositions for treating cardiovascular disease |
| 06/09/2011 | US20110135594 Oxindolyl inhibitor compounds |
| 06/09/2011 | US20110135592 Hydrolytically Degradable Polymers and Hydrogels Made Therefrom |
| 06/09/2011 | US20110135577 Superparamagnetic nanoparticles IN MEDICAL THERAPEUTICS and manufacturing method THEREOF |
| 06/09/2011 | US20110135576 Dye conjugates of template-fixed peptidomimetics |
| 06/09/2011 | US20110131928 Reduced-odor thiol compositions |
| 06/09/2011 | DE202011000728U1 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets Pancreatin pellets, especially pancreatin micro pellets |
| 06/09/2011 | DE102009056746A1 Transdermales therapeutisches System für die Verabreichung von Peptiden Transdermal therapeutic system for the administration of peptides |
| 06/09/2011 | DE102009056745A1 Transdermales therapeutisches System für die Verabreichung von Peptiden Transdermal therapeutic system for the administration of peptides |
| 06/09/2011 | CA2782814A1 Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho |
| 06/09/2011 | CA2782751A1 Transdermal therapeutic system for the administration of peptides |
| 06/09/2011 | CA2782741A1 Transdermal therapeutic system for the administration of peptides |
| 06/09/2011 | CA2782693A1 Nutritional formulation comprising a cow's milk peptide-containing hydrolysate and/or peptides derived thereof for tolerance induction |
| 06/09/2011 | CA2782691A1 Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| 06/09/2011 | CA2782676A1 Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| 06/09/2011 | CA2782527A1 Uses of hypoxia-inducible factor inhibitors |
| 06/09/2011 | CA2782459A1 Arf6 as a new target for treating alzheimer's disease |
| 06/09/2011 | CA2782424A1 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| 06/09/2011 | CA2782320A1 Compositions and methods for increasing serum half-life of fc fusion proteins |
| 06/09/2011 | CA2781493A1 Pharmaceutical compositions for the stimulation of stem cells |
| 06/09/2011 | CA2781309A1 Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema |
| 06/09/2011 | CA2780921A1 Method of regulating ppar, obesity related pathways and their associated metabolic impact |
| 06/08/2011 | EP2330213A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 06/08/2011 | EP2330197A2 Antagonistic selective binding agents of osteoprotegerin binding protein |
| 06/08/2011 | EP2330194A2 Non-sequence complementary antiviral oligonucleotides |
| 06/08/2011 | EP2330192A1 Polypeptides and polynucleotides from coagulase-negative staphylococci |
| 06/08/2011 | EP2330129A2 Anti-TNF antibodies, compositions, methods and uses |
| 06/08/2011 | EP2330127A2 Kallikrein-inhibiting Kunitz Domain proteins and nucleic acids encoding the same |
| 06/08/2011 | EP2330126A1 Protracted exendin-4 compounds |
| 06/08/2011 | EP2330124A2 Hybrid polypeptides with selectable properties |
| 06/08/2011 | EP2330123A2 HIV resistance genes |
| 06/08/2011 | EP2330121A2 Binding moieties based on Shark IgNAR domains |
| 06/08/2011 | EP2330120A2 Binding moieties based on Shark IgNAR domains |
| 06/08/2011 | EP2330119A2 Methods for obtaining thermostable enzymes, DNA polymerase I variants from thermus aquaticus having new catalytic activities, methods for obtaining the same, and applications of the same |
| 06/08/2011 | EP2330117A1 Genes of an otitis media isolate of nontypeable Haemophilus influenzae |
| 06/08/2011 | EP2330116A1 Replikin peptides and uses thereof |
| 06/08/2011 | EP2330115A1 Replikin peptides and uses thereof |
| 06/08/2011 | EP2330112A1 Collagen peptide, dipeptide, and agent for prevention of disease |
| 06/08/2011 | EP2330092A2 Medicament comprising steviol or isosteviol for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome |
| 06/08/2011 | EP2329848A1 Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes |
| 06/08/2011 | EP2329842A2 Interleukin-1 inhibitors in the treatment of diseases |
| 06/08/2011 | EP2329841A1 Survivin peptide vaccine |
| 06/08/2011 | EP2329840A1 Survivin peptide vaccine |
| 06/08/2011 | EP2329839A1 Modification of feeding behavior by GLP-1 and PYY |
| 06/08/2011 | EP2329838A2 Mutated netrin 4, fragments thereof and uses thereof as drugs |
| 06/08/2011 | EP2329837A1 Promoting bone growth |
| 06/08/2011 | EP2329832A1 Protein formulation |
| 06/08/2011 | EP2329830A2 Antisense inhibition of PTP1B expression |
| 06/08/2011 | EP2329714A1 Influence of TAJ in the neuronal functions |
| 06/08/2011 | EP2329025A1 Periostin-induced pancreatic regeneration |
| 06/08/2011 | EP2329023A1 Compositions and methods for delivery of protein-coding rnas to correct mitochondrial dysfunction |
| 06/08/2011 | EP2329015A1 Peptidomimetic macrocycles |
| 06/08/2011 | EP2328925A1 Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| 06/08/2011 | EP2328919A2 Pd-i antagonists and methods for treating infectious disease |
| 06/08/2011 | EP2328911A1 Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling |
| 06/08/2011 | EP2328910A2 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| 06/08/2011 | EP2328908A2 Treatment of amyloidoses using myelin basic protein and fragments thereof |
| 06/08/2011 | EP2328656A1 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis " |
| 06/08/2011 | EP2328611A2 Compositions and methods for treating s.pneumoniae infection |
| 06/08/2011 | EP2328609A1 Rapidly disintegrating tablets comprising lipase, amylase, and protease |
| 06/08/2011 | EP2328608A2 Use of ultrarapid acting insulin |
| 06/08/2011 | EP2328607A1 Stable formulation of a therapeutic protein |
| 06/08/2011 | EP2328606A1 Compositions and methods for treatment during non-acute periods following cns neurological injury |
| 06/08/2011 | EP2328605A1 Use of afamin for treating fertility disorders |
| 06/08/2011 | EP2328604A1 The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer |
| 06/08/2011 | EP2328603A2 Derivatives of apf and methods of use |
| 06/08/2011 | EP2328602A2 Cancer peptide therapeutics |
| 06/08/2011 | EP2328601A2 Linaclotide-containing formulations for oral administration |
| 06/08/2011 | EP2328600A1 Hig2 and urlc10 epitope peptide and vaccines containing the same |
| 06/08/2011 | EP2328595A1 Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor |
| 06/08/2011 | EP2328573A1 Antibacterial combination therapy for the treatment of gram positive bacterial infections |
| 06/08/2011 | EP2328571A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| 06/08/2011 | EP2328570A2 Method and formulation for treating adverse biological conditions |
| 06/08/2011 | EP2328566A1 Enzyme composition and application thereof in the treatment of pancreatic insufficiency |
| 06/08/2011 | EP1919513B1 Targeted vector comprising a cyclodecapeptide RAFT and an activable imaging function |
| 06/08/2011 | EP1786445B1 Live microbial microbicides |
| 06/08/2011 | EP1771200B1 Physiologically-active composition based on collagen |
| 06/08/2011 | EP1766013B1 Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases |
| 06/08/2011 | EP1573022B1 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer |
| 06/08/2011 | EP1570269B1 Methods of protecting against radiation damage using alpha thymosin |
| 06/08/2011 | EP1527346B1 Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
| 06/08/2011 | EP1502599B1 Use of mutated VEGF for antiangiogenic therapy |
| 06/08/2011 | EP1485127B1 Administration of agents for the treatment of inflammation |
| 06/08/2011 | EP1464697B1 COMPOSITION for CREATING, REGENERATING AND REPAIRING TISSUES USING A CELL-CARRYING BIOLOGICAL IMPLANT WHICH IS ENRICHED WITH A PLATELET CONCENTRATE AND SUPPLEMENTS |
| 06/08/2011 | EP1392255B1 Nanoparticles made of protein with coupled apolipoprotein e for penetration of the blood-brain barrier and methods for the production thereof |
| 06/08/2011 | EP1276765B1 Single-chain fertility hormones with variable lh activity |
| 06/08/2011 | EP1078093B1 Vaccines, immunotherapeutics and methods for using the same |
| 06/08/2011 | EP0960936B1 Reconstituted human anti-hm1.24 antibody |
| 06/08/2011 | EP0914142B1 Peptides with increased binding affinity for at least three hla-a3-like molecules |
| 06/08/2011 | CN1997665B Novel carbamylated EPO and method for its production |
| 06/08/2011 | CN1997381B Corneal neuritogenesis promoter containing PACAP and its derivative |
| 06/08/2011 | CN1852736B Immunoglobulin chimeric monomer-dimer hybrids |
| 06/08/2011 | CN1852722B Use of insulin and myristoylation PKC alpha Pseudo substrate in preparing medicine for healing skin wound |
| 06/08/2011 | CN1636058B Novel alanine transaminase enzyme and methods of use |
| 06/08/2011 | CN102089425A Biomimetic cell scaffolds |
| 06/08/2011 | CN102089323A Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC |
| 06/08/2011 | CN102089006A Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent |